Singapore, Jan. 14 -- Taiwan-based startup Leadgene Biosolutions has announced the expansion of its product portfolio following its strategic integration into Leadgene Biomedical. The expanded portfolio supports both early-stage cell line development and long-term metabolic research, enabling researchers to make more informed decisions earlier in their workflows.

For biopharmaceutical companies, Leadgene Biosolutions continues to advance its microbioreactor platform family with S.NEST(R) 2.0 and C.NEST(R) 2.0, designed for 96- and 24-well microplate-based cell line development and early-stage clone assessment.

By introducing controlled mixing at early stages where it has traditionally been difficult to implement, these platforms support...